HF Etiology and cardiac contractility modulation therapy

Area of Science:

• Cardiology
• Heart Failure Research
• Medical Device Technology

Background:

• Heart failure with reduced ejection fraction (HFrEF) remains a significant clinical challenge, necessitating advanced therapeutic strategies.
• Cardiac contractility modulation (CCM) therapy offers a potential treatment option for patients with HFrEF refractory to optimal medical therapy.

Purpose of the Study:

• To evaluate the safety and efficacy of CCM therapy in HFrEF patients, stratified by the etiology of heart failure (HF).
• To compare treatment outcomes between patients with ischemic (ICM) and non-ischemic (NICM) HFrEF undergoing CCM therapy.

Main Methods:

• A retrospective analysis of 166 patients with drug-resistant HFrEF who received CCM device implantation between 2013 and 2019.
• HF etiology was determined via coronary angiography or cardiac MRI. Outcomes including left ventricular ejection fraction (LVEF), 6-minute walking test (6MWT), and NYHA class were assessed at baseline and 12 months post-implantation.

Main Results:

• No significant difference in mortality was observed between the ICM (61.5%) and NICM (38.5%) groups.
• Patients with NICM demonstrated a significantly greater improvement in LVEF (7.7% vs. 2.0%, p < 0.001) and LV reverse remodeling compared to ICM patients at 12 months.
• Improvements in 6MWT and NYHA class were not significantly different between the groups, though factors like atrial fibrillation and COPD were associated with poorer NYHA class improvement.

Conclusions:

• CCM therapy is a viable option for drug-resistant HFrEF, with no significant difference in survival based on HF etiology.
• Patients with non-ischemic HFrEF experience superior improvements in LVEF and LV reverse remodeling following CCM implantation compared to those with ischemic HFrEF.